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ABSTRACT 
OBJECTIVES 
Multi-institutional studies are required for the validation of the Milan System for Reporting 
Salivary Gland Cytopathology (MSRSGC). 
METHODS 
A total of 1,560 fine-needle aspirations of the salivary glands were retrieved from two 
institutions for a 12-year period. The diagnoses were reclassified based on the MSRSGC. 
Risk of malignancy (ROM) for each category was calculated based on 694 histologic 
follow-up cases. 
RESULTS 
The ROM for each category was: 18.3% for nondiagnostic, 8.9% for nonneoplastic, 37.5% 
for atypia of undetermined significance (AUS), 2.9% for benign neoplasm, 40.7% for 
salivary gland neoplasm of uncertain malignant potential (SUMP), 100% for suspicious 
for malignancy, and 98.3% for malignant. The sensitivity, specificity, positive predictive 
rate, and negative predictive rates were 89%, 99%, 98%, and 96%, respectively. 
CONCLUSIONS 
The results of the current study are in keeping with the MSRSGC. The indeterminate 
categories of AUS and SUMP showed intermediate ROMs at 37.5% and 40.7%, 
respectively. 
 
 
 
 
 
 
 
 
Fine-needle aspiration (FNA) biopsy is a safe and cost-effective technique for the 
preoperative evaluation of salivary gland lesions. It is useful to differentiate between 
neoplastic and nonneoplastic lesions and to provide specific diagnoses for common 
benign and malignant neoplasms. However, cytologic interpretation of salivary gland 
FNAs can be challenging due to the diverse morphology of salivary gland tumors, 
including tumor heterogeneity and overlapping morphologic features between different 
tumor subtypes. The addition of new entities recognized by the updated 2017 World 
Health Organization classification of head and neck tumors also contributes to this 
challenge.1 In the past, the FNA diagnoses of salivary gland lesions were often 
descriptive and sometimes lacked clarity for management guidance. For these reasons, 
the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) has been 
recently developed to standardize the terminology for reporting FNA cytology of salivary 
gland and to improve the communication between clinicians and pathologists.2,3 The 
MSRSGC is a seven-tiered classification system comprising: I, nondiagnostic; II, 
nonneoplastic; III, atypia of undetermined significance (AUS); IVA, benign neoplasm; IVB, 
salivary gland neoplasm of uncertain malignant potential (SUMP); V, suspicious for 
malignancy (SM); and VI, malignant. It also provides estimated risk of malignancy (ROM) 
and clinical management recommendations for each category. Since the inception of the 
MSRSGC, there have been a few studies addressing institutions' experiences with this 
classification system.4-13 Multi-institutional studies with a large number of cases and 
surgical pathology follow-up are necessary to validate the clinical utility of this 
classification scheme. The objectives of this study were to retrospectively reclassify 
consecutive salivary gland FNAs from a 12-year period at two institutions, to assess the 
ROM for each category with surgical pathology follow-up, and to compare the differences 
for diagnostic frequency, follow-up biopsy or resection rate, and ROM in each category 
between these two institutions to further validate the MSRSGC in real-world practice. 
MATERIALS AND METHODS 
The study was approved by the Institutional Review Board (IRB) of Indiana University (IU, 
IRB No. 1802116631) and Taipei Veterans General Hospital (TVGH, IRB No. 2018-07-
009AC). A retrospective search for all salivary gland FNAs from a 12-year period (2006-
 
 
2017) in the pathology databases of the two institutions was carried out. The FNA 
aspirates were performed by radiologists, pathologists, or surgeons with or without 
ultrasound guidance. Two to four passes were routinely obtained from each lesion. Rapid 
on-site evaluation was performed for most of the IU cases but for none of the TVGH 
cases. The direct smears were prepared with conventional methods. An air-dried slide 
stained with Romanowsky-type stains (either Liu or Diff-Quik) and an alcohol-fixed slide 
stained with Papanicolaou stain was prepared for each pass. Based on the cytology 
reports and selective review of microscope slides when information from the report was 
insufficient (H. H. W. reviewed the slides from IU and J.-F. H. reviewed the slides from 
TVGH), the final diagnosis of each case was reclassified based on the MSRSGC. The 
histology follow-up (core biopsy or resection) of these cases was retrieved. The ROM of 
cases from each category was calculated. The ROM is defined as the ratio of FNAs with 
malignant follow-up to the total number of FNA cases with histology follow-up for that 
category. For calculation of the sensitivity, specificity, positive predictive rate, and 
negative predictive rate for the malignancy, we grouped the SM and malignant cases 
together as positive, and the nonneoplastic and benign neoplasm cases as negative. The 
calculations with and without the inclusion of AUS and SUMP were performed. To 
compare diagnostic frequency, follow-up biopsy or resection rate, and ROM for each 
category between the two institutions, Fisher exact tests were applied. Student t test was 
performed to compare differences between mean ages of two groups. Two-sided P 
values less than .05 were considered to be statistically significant. Statistical analyses 
were performed using R software (version 3.5.0; R Foundation, Vienna, Austria). 
RESULTS 
A total of 1,560 salivary gland aspirates were retrieved, of which 885 cases originated 
from IU and 675 cases from TVGH, including 707 female and 853 male patients, with an 
average age of 55.2 years (range, 1-98). Of the 1,560 lesions, 980 were in the parotid 
gland, 272 in the submandibular gland, three in the palate, and a specific anatomic site 
was not documented in 302 of the FNA reports. The size of the lesions measured 2.4 cm 
on average (range, 0.5-9.4 cm). 
 
 
The diagnostic frequency, biopsy or resection rate, and ROM for each category from the 
two institutions are summarized in Table 1. Overall, the final diagnosis of each FNA was 
reclassified based on the MSRSGC resulting in 294 (18.8%) cases classified 
nondiagnostic, 336 (21.5%) nonneoplastic, 60 (3.8%) AUS, 581 (37.2%) benign 
neoplasm, 92 (5.9%) SUMP, 19 (1.2%) SM, and 178 (11.4%) malignant. Based on 694 
cases with histologic follow-up, the ROM for each category was: 18.3% (number of 
malignancies/total number, 13/71) for nondiagnostic, 8.9% (7/79) for nonneoplastic, 
37.5% (15/40) for AUS, 2.9% (9/315) for benign neoplasm, 40.7% (24/59) for SUMP, 
100% (15/15) for SM, and 98.3% (113/115) for malignant. 
TABLE 1 
Reclassification of Salivary Gland Aspirates From Two Institutions in the 12-Year Period 
2006-2017 Based on the MSRSGC 
 
Overall IU TVGH 
MSRSGC 
No. 
(Over
all, 
%) 
No. of 
Histol
ogy 
Follo
w-up 
(%) 
No. of 
Malig
nant 
(ROM, 
%) 
No. 
(Over
all, 
%) 
No. of 
Histol
ogy 
Follo
w-up 
(%) 
No. of 
Malig
nant 
(ROM, 
%) 
No. 
(Over
all, 
%) 
No. of 
Histol
ogy 
Follo
w-up 
(%) 
No. of 
Malig
nant 
(ROM, 
%) 
I. 
Nondiagn
ostic  
294 
(18.8)
  
71 
(24.1)  
13 
(18.3)  
99 
(11.2)
  
24 
(24.2)  
4 
(16.7)  
195 
(28.9)
  
47 
(24.1)  
9 
(19.1)  
II. 
Nonneopl
astic  
336 
(21.5)
  
79 
(23.7)  7 (8.9)  
251 
(28.4)
  
49 
(19.5)  4 (8.2)  
85 
(12.6)
  
30 
(35.3)  3 (10)  
 
 
 
Overall IU TVGH 
MSRSGC 
No. 
(Over
all, 
%) 
No. of 
Histol
ogy 
Follo
w-up 
(%) 
No. of 
Malig
nant 
(ROM, 
%) 
No. 
(Over
all, 
%) 
No. of 
Histol
ogy 
Follo
w-up 
(%) 
No. of 
Malig
nant 
(ROM, 
%) 
No. 
(Over
all, 
%) 
No. of 
Histol
ogy 
Follo
w-up 
(%) 
No. of 
Malig
nant 
(ROM, 
%) 
III. AUS  
60 
(3.8)  
40 
(66.7)  
15 
(37.5)  
37 
(4.2)  
26 
(70.3)  
11 
(42.3)  
23 
(3.4)  
14 
(60.9)  
4 
(28.6)  
IVA. 
Benign 
neoplasm
  
581 
(37.2)
  
315 
(54.2)  9 (2.9)  
276 
(31.2)
  
154 
(55.8)  3 (1.9)  
305 
(45.2)
  
161 
(52.8)  6 (3.7)  
IVB. 
SUMP  
92 
(5.9)  
59 
(64.1)  
24 
(40.7)  
58 
(6.6)  
37 
(63.8)  
17 
(45.9)  
34 
(5%)  
22 
(64.7)  
7 
(31.8)  
V. SM  
19 
(1.2)  
15 
(78.9)  
15 
(100)  
7 
(0.8)  
4 
(57.1)  
4 
(100)  
12 
(1.8)  
11 
(91.7)  
11 
(100)  
VI. 
Malignant
  
178 
(11.4)
  
115 
(64.6)  
113 
(98.3)  
157 
(17.7)
  
98 
(62.4)  
96 
(98)  
21 
(3.1)  
17 
(81.0)  
17 
(100)  
Total  
1,560 
(100)  
694 
(44.5)  
196 
(28.2)  
885 
(100)  
392 
(44.2)  
139 
(35.5)  
675 
(100)  
302 
(44.7)  
57 
(18.9)  
 
 
 
AUS, atypia of undetermined significance; IU, Indiana University; MSRSGC, Milan 
System for Reporting Salivary Gland Cytopathology; ROM, risk of malignancy; SM, 
suspicious for malignancy; SUMP, salivary gland neoplasm of uncertain malignant 
potential; TVGH, Taipei Veterans General Hospital. 
TABLE 2 
False-Positive Cases in the Malignant Category 
Age Sex MSRSGC FNA Diagnosis Histologic Diagnosis 
16  M  Malignant  
Low-grade mucoepidermoid 
carcinoma  
Pleomorphic 
adenoma  
62  M  Malignant  Adenoid cystic carcinoma  Basal cell adenoma  
FNA, fine-needle aspiration; MSRSGC, Milan System for Reporting Salivary Gland 
Cytopathology. 
Comparing the two institutions, IU had a significantly higher diagnostic frequency in 
nonneoplastic (28.4% vs 12.6%, P < .05) and malignant (17.7% vs 3.1%, P < .05) 
categories, while TVGH had much higher diagnostic frequency in nondiagnostic (28.9% 
vs 11.2%, P < .05) and benign neoplasm category (45.2% vs 31.2%, P < .05). The follow-
up biopsy or resection rate was significantly higher in TVGH for the nonneoplastic 
category (35.3% vs 19.5%, P < .05). There were no differences in ROM for each category 
between these two institutions. 
On histologic follow-up, the most common benign neoplasm was pleomorphic adenoma 
(226/694, 32.6%), followed by Warthin tumor (114/694, 16.4%). The most common 
malignancy was metastatic squamous cell carcinoma (40/694, 5.8%), followed by 
lymphoma (35/694, 5.0%). In the malignant category, patients with metastatic squamous 
cell carcinoma were much older than patients with other malignancies (mean age, 71.0 
vs 56.4 years, P < .001). The most common primary site was the skin of head and neck. 
 
 
There were two false-positive cases in the malignant category Image 1. The second case 
was a basal cell adenoma, which was overdiagnosed as an adenoid cystic carcinoma on 
FNA Image 2. All 15 cases of SM that underwent surgery were malignant on histologic 
follow-up (ROM 100%). 
Image 1 
 
Fine-needle aspiration of right parotid gland mass was misinterpreted as a low-grade 
mucoepidermoid carcinoma. A and B, The smears show clusters of basaloid epithelial 
cells, occasional squamous cells, and abundant mucin in the background (Papanicolaou, 
×200). C, Occasional cells demonstrate cytoplasmic vacuoles (Diff-Quik, ×400). D, 
Resection of the tumor revealed a pleomorphic adenoma with extensive squamous and 
mucinous metaplasia (H&E, ×200). 
Image 2. 
 
 
 
A basal cell adenoma was misinterpreted as adenoid cystic carcinoma on fine-needle 
aspiration. Cytologic smears show small hyaline globules within the basaloid epithelium 
(A, Diff-Quik, ×400; B, Papanicolaou, ×400). C, Histologic follow-up revealed a basal cell 
adenoma with focal cribriform growth pattern containing basophilic basement membrane-
like material within the microcystic spaces (H&E, ×200). 
Among the 394 benign aspirates categorized as nonneoplastic and benign neoplasm with 
histologic follow-up, there were 16 false-negative cases, which included seven cases of 
lymphoma, four cases of carcinoma ex pleomorphic adenoma, two cases of adenoid 
cystic carcinoma, and one case each of acinic cell carcinoma, adenocarcinoma, not 
otherwise specified (NOS), and secretory carcinoma Table 3. 
 
 
TABLE 3 
False-Negative Cases in the Nonneoplastic and Benign Neoplasm Categories 
Age, y Sex MSRSGC 
FNA 
Diagnosis Histologic Diagnosis 
33  M  Nonneoplastic  RLN  Lymphoma-classic Hodgkin  
 
 
Age, y Sex MSRSGC 
FNA 
Diagnosis Histologic Diagnosis 
32  M  Nonneoplastic  RLN  Lymphoma-follicular  
71  M  Nonneoplastic  RLN  Lymphoma-follicular  
83  M  Nonneoplastic  RLN  Lymphoma-follicular  
39  F  Nonneoplastic  RLN  Lymphoma-follicular  
47  F  Nonneoplastic  RLN  Lymphoma-MALT  
16  M  Nonneoplastic  RLN  Lymphoma-T lymphoblastic  
52  F  
Benign 
neoplasm  WT  Acinic cell carcinoma  
42  F  
Benign 
neoplasm  PA  Adenoid cystic carcinoma  
43  F  
Benign 
neoplasm  PA  Adenoid cystic carcinoma  
76  F  
Benign 
neoplasm  PA  
Carcinoma ex pleomorphic 
adenoma  
29  F  
Benign 
neoplasm  PA  
Carcinoma ex pleomorphic 
adenoma  
 
 
Age, y Sex MSRSGC 
FNA 
Diagnosis Histologic Diagnosis 
60  M  
Benign 
neoplasm  PA  
Carcinoma ex pleomorphic 
adenoma  
43  M  
Benign 
neoplasm  PA  
Carcinoma ex pleomorphic 
adenoma  
63  F  
Benign 
neoplasm  PA  Low-grade adenocarcinoma, NOS  
66  M  
Benign 
neoplasm  PA  Secretory carcinoma  
 
FNA, fine-needle aspiration; MALT, mucosa-associated lymphoid tissue; MSRSGC, 
Milan System for Reporting Salivary Gland Cytopathology; NOS, not otherwise specified; 
PA, pleomorphic adenoma; RLN, reactive lymph node; WT, Warthin tumor. 
For the indeterminate categories, there were 40 cases that had histology correlation 
within the AUS category. Among these, 15 cases (37.5%) were malignant, one was 
atypical, nine were benign neoplasms, and 15 were nonneoplastic. The most common 
malignant diagnosis in the AUS category was lymphoma (seven cases), accounting for 
47% of all malignant cases in AUS category Table 4. For the SUMP category, there were 
59 cases with histologic follow-up. Among these, two (3.4%) were nonneoplastic, 33 
(55.9%) were benign neoplasm, and 24 (40.7%) were malignant. Most of the follow-up 
cases within the SUMP category were neoplastic (57/59, 96.6%) with 33 benign and 24 
malignant neoplasms Table 5. 
TABLE 4 
 
 
Histologic Correlation of Atypia in the Undetermined Significance (AUS) Category (40 
Cases) 
MSRSGC Histology Category Histologic Diagnosis No. 
AUS  Nonneoplastic, 15 cases (37.5%)  Reactive lymph node  5  
    Acute or chronic sialadenitis  5  
    IgG4-related sialadenitis  2  
    Lymphoepithelial cyst  1  
    Epidermoid cyst  1  
    Mucocele  1  
  Atypical, 1 case (2.5%)  Atypical lymphoid infiltrate  1  
  Benign neoplasm, 9 cases (22.5%)  Warthin tumor  3  
    Basal cell adenoma  2  
    Pleomorphic adenoma  1  
    Benign keratinizing lesion  1  
    Oncocytic cystadenoma  1  
    Paraganglioma  1  
 
 
MSRSGC Histology Category Histologic Diagnosis No. 
  Malignant, 15 cases (37.5%)  Lymphoma  7  
    Mucoepidermoid carcinoma  2  
    Acinic cell carcinoma  1  
    Leiomyosarcoma  1  
    Lymphoepithelial carcinoma  1  
    Metastatic melanoma  1  
    Metastatic squamous carcinoma  1  
    Papillary cystadenocarcinoma  1  
MSRSGC, Milan System for Reporting Salivary Gland Cytopathology. 
TABLE 5 
Histologic Correlation of Salivary Gland Neoplasm in the Uncertain Malignant Potential 
(SUMP) Category (59 Cases) 
MSRSGC Histology Category Histologic Diagnosis No. 
SUMP  
Nonneoplastic, 2 cases 
(3.4%)  Chronic sialadenitis  1  
    Salivary duct cyst  1  
 
 
MSRSGC Histology Category Histologic Diagnosis No. 
  
Benign neoplasm, 33 cases 
(55.9%)  Pleomorphic adenoma  16  
    Basal cell adenoma  11  
    Warthin tumor  3  
    Oncocytoma  1  
    Pilomatrixoma  1  
    Myoepithelioma  1  
  Malignant, 24 cases (40.7%)  Mucoepidermoid carcinoma  7  
    Adenoid cystic carcinoma  5  
    
Carcinoma ex pleomorphic 
adenoma  2  
    
Epithelial-myoepithelial 
carcinoma  2  
    
Metastatic basaloid squamous 
carcinoma  2  
 
 
MSRSGC Histology Category Histologic Diagnosis No. 
    Salivary duct carcinoma  2  
    Acinic cell carcinoma  1  
    Secretory carcinoma  1  
    Myoepithelial carcinoma  1  
    MALT lymphoma  1  
 
MALT, mucosa-associated lymphoid tissue; MSRSGC, Milan System for Reporting 
Salivary Gland Cytopathology. 
To distinguish between benign and malignant, with and without inclusion of AUS and 
SUMP, the sensitivity, specificity, positive predictive rate, and negative predictive rates 
were 91%, 86%, 73%, 96% and 89%, 99%, 98%, 96% respectively Table 6. 
 
 TABLE 6 
The Performance of the Milan System for Reporting Salivary Gland Cytopathology for 
Detecting Malignancy 
 
With Inclusion of AUS and 
SUMP, % 
Without Inclusion of AUS 
and SUMP, % 
Sensitivity  91  89  
 
 
 
With Inclusion of AUS and 
SUMP, % 
Without Inclusion of AUS 
and SUMP, % 
Specificity  86  99  
Positive predictive 
value  73  98  
Negative predictive 
value  96  96  
AUS, atypia of undetermined significance; SUMP, salivary gland neoplasm of uncertain 
malignant potential. 
DISCUSSION 
FNA has become widely accepted as a first-line diagnostic tool for the evaluation of 
salivary gland lesions and can provide useful information for clinical management of these 
patients. However, cytomorphologic interpretation can be challenging when dealing with 
tumors showing diverse morphology and metaplasia. The objective of the MSRSGC is to 
foster better communication between clinicians and pathologists and to improve patient 
care. It provides a standardized, tiered diagnostic framework with risk stratification for 
salivary gland FNA. The ROM for each category estimated by the authors of the 
MRSGC2 is as follows: 25% for nondiagnostic, 10% for nonneoplastic, 20% for AUS, less 
than 5% for benign neoplasm, 35% for SUMP, 60% for SM, and 90% for malignant. 
However, the actual ROMs for the MRSGC diagnostic categories that have been reported 
in the literature have ranged widely: 18% (0%-44.2%) for nondiagnostic, 8.6% (1.6%-
33.3%) for nonneoplastic, 30.1% (0%-100%) for AUS, 3.4% (1.6%-7.9%) for benign 
neoplasm, 40.3% (26.7%-50%) for SUMP, 84.8% (50%-100%) for SM, and 97.5% 
(92.3%-100%) for malignant Table 7.4-14 
TABLE 7 
 
 
Summary of Risks of Malignancy for MSRSGC Categories in Studies With Pathologic 
Follow-up Published 2017-2019 
  
Risk of Malignancy, % (No. of Malignancies/Total No.) 
Author No. 
Nondiagnos
tic 
Nonneoplas
tic AUS 
Benign 
Neoplas
m SUMP SM 
Maligna
nt 
Hollyfield 
et al5  77  37.5 (3/8)  16.7 (2/12)  
33.3 
(3/9)  
3.8 
(1/26)  
33.3 
(2/6)  
66.7 
(2/3)  
100 
(13/13)  
Layfield et 
al6  162  13.8 (4/29)  5.3 (1/19)  
20 
(3/15)  
3.6 
(2/55)  
44.4 
(4/9)  
60 
(3/5)  
93.3 
(28/30)  
Montezum
a et al7  104  25 (1/4)  33.3 (2/6)  
9.1 
(1/11)  
1.6 
(1/61)  
40 
(6/15)  
50 
(1/2)  
100 
(5/5)  
Pujani et 
al8  64  0 (0/1)  10 (1/10)  
50 
(1/2)  
2.5 
(1/40)  
50 
(1/2)  
100 
(2/2)  
100 
(7/7)  
Rohilla et 
al9  94  0 (0/1)  17.4 (4/23)  
100 
(2/2)  
7.3 
(3/41)  
50 
(1/2)  (0/0)  
96 
(24/25)  
Song et 
al10  429  17.8 (8/45)  14.3 (2/14)  
30.6 
(15/49)
  
2.2 
(4/178)  
46.4 
(26/56)
  
78.9 
(15/19
)  
98.5 
(67/68)  
Thiryayi et 
al11  283  8.5 (5/59)  1.6 (1/63)  0 (0/7)  
1.9 
(2/104)  
26.7 
(4/15)  
100 
(5/5)  
100 
(30/30)  
Vallonthai
el et al12  190  44.2 (19/43)  7.7 (1/13)  0 (0/3)  
7.9 
(5/63)  
44.4 
(4/9)  
81.5 
(22/27
)  
100 
(32/32)  
 
 
  
Risk of Malignancy, % (No. of Malignancies/Total No.) 
Author No. 
Nondiagnos
tic 
Nonneoplas
tic AUS 
Benign 
Neoplas
m SUMP SM 
Maligna
nt 
Viswanath
an et al13  373  6.7 (3/45)  7.1 (7/98)  
38.9 
(7/18)  
5 
(6/121)  
34.2 
(13/38)
  
92.9 
(13/14
)  
92.3 
(36/39)  
Current 
study  694  18.3 (13/71)  8.9 (7/79)  
37.5 
(15/40)
  
2.9 
(9/315)  
40.7 
(24/59)
  
100 
(15/15
)  
98.3 
(113/11
5)  
Overall  
2,47
0  
18.3 
(56/306)  8.3 (28/337)  
30.1 
(47/15
6)  
3.4 
(34/1,00
4)  
40.3 
(85/21
1)  
84.8 
(78/92
)  
97.5 
(355/36
4)  
MSRSGC 
estimation
3    25  10  20  <5  35  60  90  
 
AUS, atypia of undetermined significance; MSRSGC, Milan System for Reporting Salivary 
Gland Cytopathology; SM, suspicious for malignancy; SUMP, salivary gland neoplasm of 
uncertain malignant potential. 
In our study, the ROMs for the nonneoplastic and benign neoplasm categories were 8.9% 
and 2.9%, which are in keeping with the MSRSGC. The differences in ROM for these two 
categories between the two institutions were minimal (8.2% vs 10% for nonneoplastic and 
1.9% vs 3.7% for benign neoplasm). A total of 16 false-negative cases were identified. 
Among these, all seven false-negative cases for the nonneoplastic category were 
lymphoma on follow-up biopsy. These cases were interpreted as reactive lymph nodes 
based on cytomorphology on FNA. Failure to recognize abnormal lymphoid cells and to 
 
 
obtain additional aspirates for flow cytometry during the on-site evaluation was the main 
reason for these diagnostic errors. The reclassification of these cases was based on the 
original report. However, most of the cases could be better classified as AUS upon 
retrospective slide review. Reactive lymph node was the most common nonneoplastic 
diagnosis in our study, accounting for 43.8% (147/336) of the cases. Although seven 
cases of lymphoma were missed, the overall ROM for cytologic diagnosis of reactive 
lymph node in our study was still relatively low at 4.7% based on clinical and histologic 
follow-up. Lymphoma was also found to be the predominant cause of false-negative 
diagnosis in the nonneoplastic category in other studies.13,15 Of the nine false-negative 
cases within the benign neoplasm category, carcinoma ex pleomorphic adenoma (four 
cases) and adenoid cystic carcinoma (two cases) accounted for the majority of errors. All 
of these cases had been misdiagnosed as pleomorphic adenoma on FNA. Carcinoma ex 
pleomorphic adenoma was also the main contributor to the increase in ROM in the benign 
neoplasm category in the study by Viswanathan et al.13 In our study, the other two cases 
that were falsely diagnosed as pleomorphic adenoma due to the presence of focal 
metachromatic mesenchymal materials on FNA were one case of low-grade 
adenocarcinoma, NOS and one case of secretory carcinoma. The last false-negative 
case in the benign neoplasm category was an acinic cell carcinoma, which was 
misdiagnosed as Warthin tumor on FNA due to the coexistence of oncocytoid tumor cells 
and lymphocytes. 
In our study, the most common benign neoplasm was pleomorphic adenoma, comprising 
32.6% of all cases, while the most common malignant diagnoses were metastatic 
squamous cell carcinoma and lymphoma, comprising 5.8% and 5.0% of all cases, 
respectively. Rossi et al15 also found that the most frequent benign and malignant lesions 
were pleomorphic adenoma and squamous cell carcinoma, while lymphoma was reported 
as the most common malignant neoplasm by Viswanathan et al.13 Primary squamous 
cell carcinoma and lymphoma are rare. Most cases of squamous cell carcinoma and 
lymphoma in our study arose in lymph nodes located within or adjacent to the parotid 
glands or submandibular glands. 
 
 
The ROMs of SM and malignant categories were 100% and 98.3% in our study, which is 
higher than suggested in MSRSGC. False-positive cases are rare, comprising only two 
cases in our study. The first false-positive case was a pleomorphic adenoma with 
extensive squamous and mucous cell metaplasia. The corresponding FNA was 
diagnosed as low-grade mucoepidermoid carcinoma due to the presence of squamoid 
cells in a background of abundant mucinous material (Image 1). The second case was a 
monomorphic basal cell adenoma, which was overdiagnosed as an adenoid cystic 
carcinoma due to the presence of small hyaline globules on FNA smears (Image 2). Basal 
cell adenoma misinterpreted as adenoid cystic carcinoma on FNA has been previously 
reported.16 The basement membrane-like material forming hyaline globules is known to 
be a characteristic feature of adenoid cystic carcinoma but can also be seen in other 
salivary gland neoplasms, including pleomorphic adenoma, basal cell adenoma, 
myoepithelioma, polymorphous adenocarcinoma, and epithelial-myoepithelial carcinoma. 
The diagnostic category of AUS in the MSRSGC is defined as a salivary gland FNA that 
lacks either qualitative or quantitative cytomorphologic features to be diagnosed with 
confidence as either nonneoplastic or neoplastic. It encompasses a heterogeneous group 
of lesions ranging from nonneoplastic to malignant. The histologic follow-up of our 40 
AUS cases showed 37.5% nonneoplastic, 37.5% malignant, 22.5% benign neoplasm, 
and 2.5% atypical. The most common malignant diagnosis was lymphoma, accounting 
for 47% of all malignant cases in the AUS category (Table 4). In a recent study, Wang et 
al17 reported a high ROM (61%) for “atypical” salivary gland FNA based on a multi-
institutional study with 154 cases having histologic follow-up. Lymphoma also accounted 
for the most common malignant diagnosis, comprising the same rate of 47% as noted in 
our study. The ROM for the AUS category in our study was 37.5%, which is higher than 
20% suggested by the MSRSGC,3 lower than the report by Wang et al,17 and similar to 
the reports by the others.5,10,13 
SUMP is a category reserved for FNA samples that are diagnostic for a neoplasm but 
cannot be further classified as a specific histopathologic entity. The ROM for SUMP in 
our study was 40.7%, which is in keeping with most reported data.4-7,10,12,13 Most of 
the histologic follow-up diagnoses of the SUMP cases were neoplasms (96.6%), including 
 
 
33 benign neoplasms and 24 malignant neoplasms (Table 5). Among these, the most 
common benign neoplasms were pleomorphic adenoma (17 cases, 49%) and basal cell 
adenoma (11 cases, 31%), while the most common malignant neoplasms were 
mucoepidermoid carcinoma (seven cases, 30%) and adenoid cystic carcinoma (five 
cases, 22%). 
There might be geographic differences between eastern and western countries in the 
distribution of diagnoses among each of the MSRSGC categories. In our study, IU 
recorded a significantly higher diagnostic frequency in the nonneoplastic (28.5% vs 
12.6%) and malignant (17.7% vs 3.1%) categories (P < .05), while TVGH recorded a 
much higher diagnostic frequency in nondiagnostic (28.9% vs 11.1%) and benign 
neoplasm (45.2% vs 31.2%) categories (P < .05). However, there were no significant 
differences in ROM for each category between these two institutions. At IU, we provide 
on-site evaluation for most of the salivary gland FNAs, which might explain the lower 
nondiagnostic rate at IU compared to that of TVGH, where on-site evaluation of the FNA 
was not routinely performed. 
To the best of our knowledge, here we report the largest retrospective series of salivary 
gland FNA reclassified based on the newly established MSRSGC. The MSRSGC appears 
to be a useful tool to provide uniform terminology for the salivary gland lesions sampled 
by FNA. Without the inclusion of AUS and SUMP categories, our study demonstrated 
high sensitivity, specificity, positive predictive rate, and negative predictive rate for 
detecting malignancy at 89%, 99%, 98%, and 96%, respectively. The AUS and SUMP 
categories accounted for only small proportions of cases (3.8% for AUS and 5.9% for 
SUMP). The ROMs were intermediate at 37.5% for AUS and 40.7% for SUMP, 
respectively. Although both AUS and SUMP showed similar ROM in our study, the lesions 
in the AUS group were more heterogeneous. Nonneoplastic lesions accounted for 37.5% 
of the cases in the AUS group, while only 3.4% of the cases in SUMP. Because most 
lesions diagnosed as SUMP turn out to be neoplastic with a moderate ROM, the 
management recommendation of conservative surgery and frozen section seems to be 
appropriate. For AUS cases, a careful clinicoradiologic correlation, ideally discussed in a 
multidisciplinary team meeting, is warranted. If the image study suggests an epithelial 
 
 
neoplasm, conservative surgery should be considered. If lymphoma is suspected, core or 
excisional biopsy with flow cytometry study might be the management of choice. 
Otherwise, clinical follow-up with repeat FNA is also a viable option for patients with AUS 
diagnosis. The limitation of this study is its retrospective design and we did not review 
slides from all of the cases; in particular, nondiagnostic, nonneoplastic, and most 
pleomorphic adenoma and Warthin tumor cases were not included. Future prospective 
studies with clinical follow-up are necessary to assess the performance of this new 
classification scheme. 
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